Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine bill

This article was originally published in The Tan Sheet

Executive Summary

House Energy & Commerce/health subcommittee approves by voice vote on Nov. 9 the Domestic Chemical Diversion Control Act (HR 3216), clearing the measure for full committee consideration. The bill, which is supported by NDMA, expands the authority of the Drug Enforcement Agency to control the distribution of legal drugs -- such as OTC asthma drugs containing ephedrine -- that are used in the manufacture of illegal street drugs such as hallucinogen methcathinone (CAT). Recently, the ShopKo chain removed ephedrine- containing products from OTC shelves at its 117 pharmacies, citing "evidence" that OTC availability "has allowed it to be used in illegal and dangerous ways.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel